Yang Liu1, Gang Xiao2, Jia-Wei Zhou1, Jian-Kun Yang1, Li Lu3, Jun Bian1, Lin Zhong4, Qing-Zhu Wei4, Qi-Zhao Zhou1, Kang-Yi Xue1, Wen-Bing Guo1, Ming Xia1, Jun-Hao Zhou1, Ji-Ming Bao1, Cheng Yang1, Cun-Dong Liu1, Ming-Kun Chen5. 1. Department of Urology, The Third Affiliated Hospital, Southern Medical University, Guangzhou, China. 2. Department of Laboratory Medicine, The Third Affiliated Hospital, Southern Medical University, Guangzhou, China. 3. Department of Urology, The Sixth Affiliated Hospital of Sun Yat-sen University, Guangzhou, China. 4. Department of Pathology, The Third Affiliated Hospital, Southern Medical University, Guangzhou, China. 5. Department of Urology, The Third Affiliated Hospital, Southern Medical University, Guangzhou, China, chenmk1@smu.edu.cn.
Abstract
OBJECTIVE: To investigate the optimal age for the baseline serum prostate-specific antigen (PSA) test and for repeat screening and its economic burden in a single center in China. MATERIALS AND METHODS: 35,533 men with PSA screening were retrospectively enrolled in this study. Follow-ups were conducted in 1,586 men with PSA >4 ng/mL, and receiver-operating characteristic (ROC) curves were employed to investigate the optimal cutoffs. RESULTS: ROC analysis indicated that the optimal age for initial PSA screening was 57.5 years (AUC = 0.84), 62.5 years (AUC = 0.902), 60.5 years (AUC = 0.909), and 61.5 years (AUC = 0.890) for individuals with PSA >4 and >10 ng/mL, a diagnosis of prostate cancer (PCa), and clinically significant PCa defined as the focus events, respectively. For Chinese men aged 50-59, 60-69, and >70 years, the initial PSA levels of 1.305 ng/mL (AUC = 0.699), 1.975 ng/mL (AUC = 0.711), and 2.740 ng/mL (AUC = 0.720) might have a PSA velocity >0.75 ng/mL per year during the follow-up. In addition, the total cost amounts to CNY 13,609,260 in these cases, but only 60 of the 35,533 (0.17%) men gained benefit from PSA screening. CONCLUSION: In our opinion, the optimal starting age for initial PSA testing was 57.5 years. The necessity for repeat screening should be based on the first PSA level depending on age. A cost--benefit analysis should be included in population-based screening.
OBJECTIVE: To investigate the optimal age for the baseline serum prostate-specific antigen (PSA) test and for repeat screening and its economic burden in a single center in China. MATERIALS AND METHODS: 35,533 men with PSA screening were retrospectively enrolled in this study. Follow-ups were conducted in 1,586 men with PSA >4 ng/mL, and receiver-operating characteristic (ROC) curves were employed to investigate the optimal cutoffs. RESULTS: ROC analysis indicated that the optimal age for initial PSA screening was 57.5 years (AUC = 0.84), 62.5 years (AUC = 0.902), 60.5 years (AUC = 0.909), and 61.5 years (AUC = 0.890) for individuals with PSA >4 and >10 ng/mL, a diagnosis of prostate cancer (PCa), and clinically significant PCa defined as the focus events, respectively. For Chinese men aged 50-59, 60-69, and >70 years, the initial PSA levels of 1.305 ng/mL (AUC = 0.699), 1.975 ng/mL (AUC = 0.711), and 2.740 ng/mL (AUC = 0.720) might have a PSA velocity >0.75 ng/mL per year during the follow-up. In addition, the total cost amounts to CNY 13,609,260 in these cases, but only 60 of the 35,533 (0.17%) men gained benefit from PSA screening. CONCLUSION: In our opinion, the optimal starting age for initial PSA testing was 57.5 years. The necessity for repeat screening should be based on the first PSA level depending on age. A cost--benefit analysis should be included in population-based screening.
Authors: M Wenzel; C Humke; S Wicker; J Mani; T Engl; G Hintereder; T J Vogl; P Wild; J Köllermann; C Rödel; S Asgharie; L Theissen; M Welte; L A Kluth; P Mandel; F K H Chun; F Preisser; A Becker Journal: Urologe A Date: 2020-10 Impact factor: 0.639